Scilex Holding Company Business Combination, Recognized Identifiable Assets Acquired, Goodwill, and Liabilities Assumed, Net
Scilex Holding Company (SCLX) had Business Combination, Recognized Identifiable Assets Acquired, Goodwill, and Liabilities Assumed, Net of $73.40 million as of 2025-12-31, per its 10-K filed 2026-04-10.
Financial Statements › Notes › Business Combination, Asset Acquisition, Transaction between Entities under Common Control, and Joint Venture Formation
us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredGoodwillAndLiabilitiesAssumedNet · last filed 2026-04-10
- 2025-12-31: Business Combination, Recognized Identifiable Assets Acquired, Goodwill, and Liabilities Assumed, Net $73.40M.
| Period end | Business Combination, Recognized Identifiable Assets Acquired, Goodwill, and Liabilities Assumed, Net |
|---|---|
| 2025-12-31 | $73.40M 10-K · filed 2026-04-10 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Metagenomi Therapeutics, Inc. (MGX) | United States | $0.044B | -0.48 |
| LeonaBio, Inc. (LONA) | United States | $0.047B | -0.61 |
| Instil Bio, Inc. (TIL) | United States | $0.048B | -1.73 |
| Tevogen Inc. (TVGN) | United States | $0.049B | |
| aTYR PHARMA INC (ATYR) | United States | $0.033B | -0.98 |
| Quince Therapeutics, Inc. (QNCX) | United States | $0.031B | |
| CEL SCI CORP (CVM) | United States | $0.030B | -0.81 |
| Inmune Bio, Inc. (INMB) | United States | $0.056B | -2.48 |
| ImageneBio, Inc. (IMA) | United States | $0.056B | -1.31 |
| BioAtla, Inc. (BCAB) | United States | $0.058B | -0.21 |